{"id":40298,"date":"2025-08-28T15:29:04","date_gmt":"2025-08-28T07:29:04","guid":{"rendered":"https:\/\/flcube.com\/?p=40298"},"modified":"2025-08-28T15:29:05","modified_gmt":"2025-08-28T07:29:05","slug":"harbourbiomed-reports-327-revenue-surge-launches-hcab%e2%80%91based-elance-therapeutics","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40298","title":{"rendered":"HarbourBioMed Reports 327\u202f% Revenue Surge, Launches HCAb\u2011Based \u00c9lanc\u00e9 Therapeutics"},"content":{"rendered":"\n

Harbour BioMed (HKG: 2142<\/a>) on Aug. 27, 20025 released its first\u2011half 2025 financial results, reporting a RMB\u202f725\u202fmillion<\/strong> (\u2248USD\u202f101\u202fm) revenue \u2013 a 327\u202f%<\/strong> year\u2011on\u2011year increase \u2013 and a RMB\u202f523\u202fmillion<\/strong> (\u2248USD\u202f73\u202fm) profit, a 51\u2011fold<\/strong> rise over the same period last year. Cash reserves climbed to RMB\u202f2.291\u202fbillion<\/strong> (\u2248USD\u202f320\u202fm), up 92\u202f%<\/strong> from the end of 2024.<\/p>\n\n\n\n

Financial Highlights<\/h3>\n\n\n\n
Metric<\/th>H1\u202f2025<\/th>YoY % Change<\/th><\/tr><\/thead>
Revenue<\/td>RMB\u202f725\u202fm<\/td>+327\u202f%<\/td><\/tr>
Net Profit<\/td>RMB\u202f523\u202fm<\/td>+5\u202f100\u202f%<\/td><\/tr>
Cash & Cash\u2011Equivalents<\/td>RMB\u202f2.291\u202fb<\/td>+92\u202f%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The results underscore Harbour\u2019s accelerated growth trajectory driven by its portfolio of HCAb\u2011based bispecific antibodies and expanding commercial partnerships.<\/p>\n\n\n\n

\u00c9lanc\u00e9 Therapeutics \u2013 A New Frontier in Metabolic Disease<\/h3>\n\n\n\n

In March, Harbour announced the creation of \u00c9lanc\u00e9 Therapeutics<\/strong>, a spin\u2011off that will harness Harbour\u2019s proprietary HCAb<\/strong> platform to develop next\u2011generation treatments for obesity and related metabolic disorders. The strategy focuses on preserving lean muscle mass and achieving durable weight\u2011loss efficacy, addressing unmet needs in the current therapeutic landscape.<\/p>\n\n\n\n

Strategic Licensing & Collaboration Portfolio<\/h3>\n\n\n\n
Month<\/th>Partner<\/th>Deal<\/th>Scope<\/th><\/tr><\/thead>
Jan\u202f2025<\/td>Windward Bio<\/td>Global license for HBM9378 \/ SKB378<\/strong> (WIN378)<\/td>Excludes Greater China, certain SEA & West\u2011Asia markets<\/td><\/tr>
Feb\u202f2025<\/td>Insilico Medicine<\/td>AI\u2011powered antibody discovery partnership<\/td>Accelerates novel therapeutic discovery<\/td><\/tr>
Mar\u202f2025<\/td>AstraZeneca<\/td>Co\u2011development of next\u2011generation multispecific antibodies<\/td>Immunological & oncological indications<\/td><\/tr>
Jun\u202f2025<\/td>Otsuka Pharma<\/td>Global collaboration on HBM7020<\/strong> (BCMAxCD3)<\/td>Autoimmune disease pipeline<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

These agreements position Harbour to monetize its HCAb technology across a spectrum of indications while expanding its global footprint.<\/p>\n\n\n\n

Outlook<\/h3>\n\n\n\n

Harbour\u2019s robust cash position and pipeline depth provide a strong foundation for continued growth. The company plans to advance \u00c9lanc\u00e9\u2019s obesity program into Phase\u202fI by Q3\u202f2026 and expects to further expand its licensing network throughout 2025.-Fineline Info & Tech<\/a><\/p>\n\n\n\n